These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 114583)

  • 21. The structural events associated with the attachment of complement components to cell membranes in reactive lysis.
    Dourmashkin RR
    Immunology; 1978 Aug; 35(2):205-12. PubMed ID: 750370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lipoproteins and C567-INH activity.
    Lint TF; Behrends CL; Gewurz H
    J Immunol; 1977 Sep; 119(3):883-8. PubMed ID: 561124
    [No Abstract]   [Full Text] [Related]  

  • 23. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation of late complement components by affinity chromatography: I. Purification of the human complement component C9 and production of a C9-defective human serum.
    Rauterberg EW; Schieck C; Hänsch G
    Z Immunitatsforsch Immunobiol; 1979 Jun; 155(5):365-77. PubMed ID: 112795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.
    Bhakdi S; Käflein R; Halstensen TS; Hugo F; Preissner KT; Mollnes TE
    Clin Exp Immunol; 1988 Dec; 74(3):459-64. PubMed ID: 2466593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The C5b-9 complex: subunit composition of the classical and alternative pathway-generated complex.
    Podack ER; Kolb WP; Muller-Eberhard HJ
    J Immunol; 1976 May; 116(5):1431-4. PubMed ID: 1270802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between channel size and the number of C9 molecules in the C5b-9 complex.
    Ramm LE; Whitlow MB; Mayer MM
    J Immunol; 1985 Apr; 134(4):2594-9. PubMed ID: 2579147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the number of lytic sites in biconcave and spheroid erythrocyte ghosts after complement lysis.
    Bauer J; Podack ER; Valet G
    J Immunol; 1979 May; 122(5):2032-6. PubMed ID: 448115
    [No Abstract]   [Full Text] [Related]  

  • 30. Preservation of C3, C5, and C5a functional activities by a new radiolabeling method; demonstration of C5 products in complement-activated serum.
    Kreutzer DL; Kunkel S; Ward PA; Showell H; McLean RH
    J Immunol; 1979 Nov; 123(5):2278-82. PubMed ID: 489983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The complement system in rainbow trout (Salmo gairdneri). II. Purification and characterization of the fifth component (C5).
    Nonaka M; Natsuume-Sakai S; Takahashi M
    J Immunol; 1981 Apr; 126(4):1495-8. PubMed ID: 7204972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
    Hammer CH; Abramovitz AS; Mayer MM
    J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of refolding conformers of complement protein C9 during insertion into membranes.
    Laine RO; Esser AF
    Nature; 1989 Sep; 341(6237):63-5. PubMed ID: 2475785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.
    Ballow M; Cochrane CG
    J Immunol; 1969 Nov; 103(5):944-52. PubMed ID: 4981797
    [No Abstract]   [Full Text] [Related]  

  • 36. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
    Tomlinson S; Whitlow MB; Nussenzweig V
    J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of solute diffusion across the C5b-9 membrane lesion of complement: evidence that individual C5b-9 complexes do not function as discrete, uniform pores.
    Sims PJ; Lauf PK
    J Immunol; 1980 Dec; 125(6):2617-25. PubMed ID: 7430641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.